Update on Familial Adenomatous Polyposis-Associated Desmoid Tumors

Abstract

Desmoid tumors (DT) represent the second high risk of tumor in familial adenomatous polyposis (FAP) patients. Although FAP-associated DTs (FAP-DT) are caused by germline mutations in the adenomatous polyposis coli (APC) gene, extracolonic manifestations, sex, family history, genotype, and the ileal pouch anal anastomosis procedure are all linked to the development of DTs in FAP patients. Multidisciplinary management has replaced aggressive surgery as the preferred treatment of DTs. There is growing evidence to support the use of active surveillance strategy as first-line treatment for FAP-DT patients. Radiotherapy for intra-abdominal desmoids is now rarely used because of severe late toxicity. Pharmacotherapy, however, represents a promising future with the improvement of traditional cytotoxic drugs and the investigation of targeted drugs. Although nonsurgery treatment has been used widely nowadays, surgery remains the mainstay when symptomatic or life-threatening DTs are present. Further research will be needed for more optimal clinical practice.

Keywords

desmoid tumors - familial adenomatous polyposis - APC - treatment

Publikationsverlauf

Artikel online veröffentlicht:
17. April 2023

• References

• 1 Rosa F, Martinetti C, Piscopo F. et al. Multimodality imaging features of desmoid tumors: a head-to-toe spectrum. Insights Imaging 2020; 11 (01) 103
• 2 Elayi E, Manilich E, Church J. Polishing the crystal ball: knowing genotype improves ability to predict desmoid disease in patients with familial adenomatous polyposis. Dis Colon Rectum 2009; 52 (10) 1762-1766
• 3 Sinha A, Tekkis PP, Gibbons DC, Phillips RK, Clark SK. Risk factors predicting desmoid occurrence in patients with familial adenomatous polyposis: a meta-analysis. Colorectal Dis 2011; 13 (11) 1222-1229
• 4 Church J, Xhaja X, LaGuardia L, O'Malley M, Burke C, Kalady M. Desmoids and genotype in familial adenomatous polyposis. Dis Colon Rectum 2015; 58 (04) 444-448
• 5 Sommovilla J, Liska D, Jia X. et al. IPAA is more “desmoidogenic” than ileorectal anastomosis in familial adenomatous polyposis. Dis Colon Rectum 2022; 65 (11) 1351-1361
• 6 Braschi-Amirfarzan M, Keraliya AR, Krajewski KM. et al. Role of imaging in management of desmoid-type fibromatosis: a primer for radiologists. Radiographics 2016; 36 (03) 767-782
• 7 Shin R, Cho HS, Kim DW. et al. Does routine colonoscopy help diagnose familial adenomatous polyposis in patients presenting with desmoid tumors but no gastrointestinal symptoms?. Int J Colorectal Dis 2017; 32 (01) 151-154
• 8 van Houdt WJ, Wei IH, Kuk D. et al. Yield of colonoscopy in identification of newly diagnosed desmoid-type fibromatosis with underlying familial adenomatous polyposis. Ann Surg Oncol 2019; 26 (03) 765-771
• 9 Desmoid Tumor Working Group. The management of desmoid tumours: a joint global consensus-based guideline approach for adult and paediatric patients. Eur J Cancer 2020; 127: 96-107
• 10 Cojocaru E, Gennatas S, Thway K. et al. Approach to screening for familial adenomatous polyposis (FAP) in a cohort of 226 patients with desmoid-type fibromatosis (DF): experience of a specialist center in the UK. Fam Cancer 2022; 21 (01) 69-74
• 11 Kasper B, Baumgarten C, Garcia J. et al; Desmoid Working Group. An update on the management of sporadic desmoid-type fibromatosis: a European Consensus Initiative between Sarcoma PAtients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG). Ann Oncol 2017; 28 (10) 2399-2408
• 12 von Mehren M, Kane JM, Bui MM. et al. NCCN Guidelines Insights: Soft Tissue Sarcoma, Version 1.2021. J Natl Compr Canc Netw 2020; 18 (12) 1604-1612
• 13 Nieuwenhuis MH, Mathus-Vliegen EM, Baeten CG. et al. Evaluation of management of desmoid tumours associated with familial adenomatous polyposis in Dutch patients. Br J Cancer 2011; 104 (01) 37-42
• 14 Burtenshaw SM, Cannell AJ, McAlister ED. et al. Toward observation as first-line management in abdominal desmoid tumors. Ann Surg Oncol 2016; 23 (07) 2212-2219
• 15 Church J, Lynch C, Neary P, LaGuardia L, Elayi E. A desmoid tumor-staging system separates patients with intra-abdominal, familial adenomatous polyposis-associated desmoid disease by behavior and prognosis. Dis Colon Rectum 2008; 51 (06) 897-901
• 16 Quintini C, Ward G, Shatnawei A. et al. Mortality of intra-abdominal desmoid tumors in patients with familial adenomatous polyposis: a single center review of 154 patients. Ann Surg 2012; 255 (03) 511-516
• 17 Saito Y, Hinoi T, Ueno H. et al. Risk factors for the development of desmoid tumor after colectomy in patients with familial adenomatous polyposis: multicenter retrospective cohort study in Japan. Ann Surg Oncol 2016; 23 (Suppl. 04) 559-565
• 18 Xie M, Chen Y, Wei W. et al. Does ileoanal pouch surgery increase the risk of desmoid in patients with familial adenomatous polyposis?. Int J Colorectal Dis 2020; 35 (08) 1599-1605
• 19 Latchford AR, Sturt NJ, Neale K, Rogers PA, Phillips RK. A 10-year review of surgery for desmoid disease associated with familial adenomatous polyposis. Br J Surg 2006; 93 (10) 1258-1264
• 20 Rodriguez-Bigas MA, Mahoney MC, Karakousis CP, Petrelli NJ. Desmoid tumors in patients with familial adenomatous polyposis. Cancer 1994; 74 (04) 1270-1274
• 21 Zhao M, Zhu G, Zhuang A, Tong H, Fang Y, Zhang Y. Risk factors for recurrence of abdominal aggressive fibromatosis after radical surgery: An 8-year observational study from a Chinese high-volume sarcoma center. J Clin Transl Res 2022; 8 (05) 339-343
• 22 Bishop AJ, Landry JP, Roland CL. et al. Certain risk factors for patients with desmoid tumors warrant reconsideration of local therapy strategies. Cancer 2020; 126 (14) 3265-3273
• 23 Nishida Y, Hamada S, Kawai A. et al. Risk factors of local recurrence after surgery in extraabdominal desmoid-type fibromatosis: a multicenter study in Japan. Cancer Sci 2020; 111 (08) 2935-2942
• 24 Chi Z, Mangus RS, Kubal CA, Chen S, Lin J. Multivisceral transplant is a viable treatment option for patients with non-resectable intra-abdominal fibromatosis. Clin Transplant 2018; 32 (03) e13186
• 25 Cheng C, Guo S, Kollie DEGB. et al. Ex vivo resection and intestinal autotransplantation for a large mesenteric desmoid tumor secondary to familial adenomatous polyposis: a case report and literature review. Medicine (Baltimore) 2018; 97 (20) e10762
• 26 Janousek L, Novotny R, Kudla M. et al. Familial adenomatous polyposis and desmoid tumor treated with multivisceral transplantation and kidney autotransplantation: case report and literature review. Case Rep Surg 2019; 2019: 6064720
• 27 Bates JE, Morris CG, Iovino NM. et al. Radiation therapy for aggressive fibromatosis: the association between local control and age. Int J Radiat Oncol Biol Phys 2018; 100 (04) 997-1003
• 28 Bishop AJ, Zarzour MA, Ratan R. et al. Long-term outcomes for patients with desmoid fibromatosis treated with radiation therapy: a 10-year update and re-evaluation of the role of radiation therapy for younger patients. Int J Radiat Oncol Biol Phys 2019; 103 (05) 1167-1174
• 29 Seidensaal K, Harrabi SB, Weykamp F. et al. Radiotherapy in the treatment of aggressive fibromatosis: experience from a single institution. Radiat Oncol 2020; 15 (01) 143
• 30 Gan M, Boothe D, Neklason DW. et al. Outcomes and complications of radiation therapy in patients with familial adenomatous polyposis. J Gastrointest Oncol 2017; 8 (04) 643-649
• 31 Janinis J, Patriki M, Vini L, Aravantinos G, Whelan JS. The pharmacological treatment of aggressive fibromatosis: a systematic review. Ann Oncol 2003; 14 (02) 181-190
• 32 Hansmann A, Adolph C, Vogel T, Unger A, Moeslein G. High-dose tamoxifen and sulindac as first-line treatment for desmoid tumors. Cancer 2004; 100 (03) 612-620
• 33 Quast DR, Schneider R, Burdzik E, Hoppe S, Möslein G. Long-term outcome of sporadic and FAP-associated desmoid tumors treated with high-dose selective estrogen receptor modulators and sulindac: a single-center long-term observational study in 134 patients. Fam Cancer 2016; 15 (01) 31-40
• 34 Skapek SX, Anderson JR, Hill DA. et al. Safety and efficacy of high-dose tamoxifen and sulindac for desmoid tumor in children: results of a Children's Oncology Group (COG) phase II study. Pediatr Blood Cancer 2013; 60 (07) 1108-1112
• 35 Mori Y, Amano K, Chikatani K. et al. Recent trends in the morbidity and mortality in patients with familial adenomatous polyposis: a retrospective single institutional study in Japan. Int J Clin Oncol 2022; 27 (06) 1034-1042
• 36 Penel N, Le Cesne A, Bui BN. et al. Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up. Ann Oncol 2011; 22 (02) 452-457
• 37 Gounder MM, Mahoney MR, Van Tine BA. et al. Sorafenib for advanced and refractory desmoid tumors. N Engl J Med 2018; 379 (25) 2417-2428
• 38 Toulmonde M, Pulido M, Ray-Coquard I. et al. Pazopanib or methotrexate-vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study. Lancet Oncol 2019; 20 (09) 1263-1272
• 39 Jo J-C, Hong YS, Kim K-P. et al. A prospective multicenter phase II study of sunitinib in patients with advanced aggressive fibromatosis. Invest New Drugs 2014; 32 (02) 369-376
• 40 Braggio D, Koller D, Jin F. et al. Autophagy inhibition overcomes sorafenib resistance in S45F-mutated desmoid tumors. Cancer 2019; 125 (15) 2693-2703
• 41 Schut AW, Vriends ALM, Sacchetti A. et al. In desmoid-type fibromatosis cells sorafenib induces ferroptosis and apoptosis, which are enhanced by autophagy inhibition. Eur J Surg Oncol 2022; 48 (07) 1527-1535
• 42 Kwon J, Lee JH, Lee YH. et al. Whole-genome and transcriptome sequencing identified NOTCH2 and HES1 as potential markers of response to imatinib in desmoid tumor (aggressive fibromatosis): a phase II trial study. Cancer Res Treat 2022; 54 (04) 1240-1255
• 43 Mir O, Honoré C, Chamseddine AN. et al. Long-term outcomes of oral vinorelbine in advanced, progressive desmoid fibromatosis and influence of CTNNB1 mutational status. Clin Cancer Res 2020; 26 (23) 6277-6283
• 44 Napolitano A, Provenzano S, Colombo C. et al. Familial adenomatosis polyposis-related desmoid tumours treated with low-dose chemotherapy: results from an international, multi-institutional, retrospective analysis. ESMO Open 2020; 5 (01) e000604
• 45 Gega M, Yanagi H, Yoshikawa R. et al. Successful chemotherapeutic modality of doxorubicin plus dacarbazine for the treatment of desmoid tumors in association with familial adenomatous polyposis. J Clin Oncol 2006; 24 (01) 102-105
• 46 Garbay D, Le Cesne A, Penel N. et al. Chemotherapy in patients with desmoid tumors: a study from the French Sarcoma Group (FSG). Ann Oncol 2012; 23 (01) 182-186
• 47 Villalobos VM, Hall F, Jimeno A. et al. Long-term follow-up of desmoid fibromatosis treated with PF-03084014, an oral gamma secretase inhibitor. Ann Surg Oncol 2018; 25 (03) 768-775
• 48 Kummar S, O'Sullivan Coyne G, Do KT. et al. Clinical activity of the γ-secretase inhibitor PF-03084014 in adults with desmoid tumors (aggressive fibromatosis). J Clin Oncol 2017; 35 (14) 1561-1569
• 49 Takahashi T, Prensner JR, Robson CD, Janeway KA, Weigel BJ. Safety and efficacy of gamma-secretase inhibitor nirogacestat (PF-03084014) in desmoid tumor: report of four pediatric/young adult cases. Pediatr Blood Cancer 2020; 67 (10) e28636
• 50 Naert T, Tulkens D, Van Nieuwenhuysen T. et al. CRISPR-SID: identifying EZH2 as a druggable target for desmoid tumors via in vivo dependency mapping. Proc Natl Acad Sci U S A 2021; 118 (47) e2115116118
• 51 Siozopoulou V, Marcq E, Jacobs J. et al. Desmoid tumors display a strong immune infiltration at the tumor margins and no PD-L1-driven immune suppression. Cancer Immunol Immunother 2019; 68 (10) 1573-1583